Compounded Tirzepatide

Deep dive

Compounded Tirzepatide: complete reference

Compounded tirzepatide is a custom-prepared formulation of tirzepatide active ingredient by state-licensed compounding pharmacies, paralleling compounded semaglutide in structure but with significantly more regulatory pressure. Eli Lilly aggressively defended its tirzepatide patent and FDA-approved Zepbound/Mounjaro brand position against compounded versions, filing lawsuits against multiple compounding manufacturers and pharmacies. The FDA resolved the tirzepatide shortage in December 2024, eliminating the legal basis для most mass compounding under 503A shortage exemptions. By 2026, most major telehealth platforms have transitioned away from compounded tirzepatide toward LillyDirect Zepbound ($349-499/month vial program) — which provides FDA-approved access at competitive cash-pay pricing. Some smaller compounders continue serving existing patients, but new-patient compounded tirzepatide programs have largely contracted. Patients on compounded tirzepatide should consider transition to FDA-approved Zepbound via LillyDirect для regulatory clarity and supply continuity.

In practice

In 2024 you could get compounded tirzepatide at $250/month easily. In 2026, most providers route you to LillyDirect Zepbound at $349-499/month for FDA-approved version.

Clinical context

Compounded tirzepatide market has contracted dramatically. LillyDirect is preferred path для FDA-approved tirzepatide cash-pay access.